Effects of recombinant human interferon α2b atomization on serum cytokines and peripheral blood immune cells in children with HFMD

• Main Authors: Wen-Di Zhang, Xiao Yu, Zai-Sheng Cai
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2018-05-01
• Series: Journal of Hainan Medical University
• Subjects: Hand-foot-and-mouth disease; Interferon α2b; Inflammatory response; Immune response
• Online Access: http://www.hnykdxxb.com/PDF/201805/11.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To study the effects of recombinant human interferon α2b atomization on serum cytokines and peripheral blood immune cells in children with HFMD. Methods: Children who were diagnosed with hand-foot-and-mouth disease in Tongji Hospital® Tongji Medical College Huazhong University of Science & Technology between June 2014 and August 2017 were selected as the research subjects and randomly divided into the interferon α2b group who accepted human recombinant interferon α2b atomization combined with conventional symptomatic treatment and the control group who accepted conventional symptomatic treatment. The contents of cytokines in serum and the contents of immune cells in peripheral blood were determined before treatment as well as 3 days and 5 days after treatment. Results: 3 days and 5 days after treatment, IL-6, IL-13, TNF-α, CRP, MCP-1, VCAM-1 and ICAM-1 contents in serum as well as CD19+CD24highCD27+B cell contents in peripheral blood of both groups of children were greatly lower than those before treatment whereas CD3+CD4+T cell, CD3+CD8+T cell and CD16+CD56+NK cell contents in peripheral blood were higher than those before treatment, and IL-6, IL-13, TNF-α, CRP, MCP-1, VCAM-1 and ICAM-1 contents in serum as well as CD19+CD24highCD27+B cell contents in peripheral blood of interferon α2b group were significantly lower than those of control group whereas CD3+CD4+T cell, CD3+CD8+T cell and CD16+CD56+NK cell contents in peripheral blood were higher than those of control group. Conclusion: Recombinant human interferon α2b atomization treatment of HFMD can reduce the inflammatory response and improve the immune response.